醫用鈦合金的微弧氧化膜層組織及其磨損性能
發布人：上海艾荔艾合金股份有限公司www.shailiai.cn
更新時間：2016-01-14
采用微弧氧化方法對醫用鈦合金表面進行改性，利用X射線衍射分析(XRD)、掃描電鏡(SEM)對微弧氧化膜層的表面形貌和化學成分進行分析，通過小振幅往復摩擦磨損試驗測量膜層的耐磨損性能。
醫用鈦合金的微弧氧化膜層組織及其磨損性能Microstructure and its wear property of micro-arc oxidation?coating on biomedical titanium alloy采用微弧氧化方法對醫用鈦合金表面進行改性，利用X射線衍射分析(XRD)、掃描電鏡(SEM)對微弧氧化膜層的表面形貌和化學成分進行分析，通過小振幅往復摩擦磨損試驗測量膜層的耐磨損性能。結果表明：鈦合金經過微弧氧化表面處理后，所得膜層存在不同尺寸的放電微孔，氧化膜內層相對外層較為致密；膜層主要由大量金紅石型TiO2相、非晶相SiO2及少量銳鈦礦型TiO2相組成；與基體相比，微弧氧化膜層的初期摩擦因數從0.7降低至0.1，耐磨性提高。
The coating prepared by micro-arc oxidation (MAO) on biomedical titanium alloy was investigated. The surface morphology and chemical composition of MAO coating were analyzed by X-ray diffractometry and scanning electron microscopy (SEM). The anti-wear property of the coating was measured through small amplitude oscillatory reciprocating friction and wear test. The results show that the MAO coating has some micropores with different dimensions and the inner layer of the coating is denser compared with the outer layer. The composition of the coating comprises majority of rutile TiO2?and amorphous phase SiO2. A fraction of the composition is anatase TiO2. The preliminary friction coefficient of the coating decreases from 0.7 to 0.1. The micro-arc oxidation treatment improves the anti-wear property of the titanium alloy.
作為值得信賴的合作伙伴和高品質金屬合金的半成品供應商，艾荔艾擁有完善的服務體系和專業的團隊。在同客戶交易的過程中，我們力求根據不同的應用需求將我們的產品做到精益求精。針對當前和未來的市場需求，艾荔艾致力于為客戶提供最佳的金屬材料解決方案。
AILIAI has been a reliable partner and supplier of sophisticated and high-quality semi-finished products maed of alloys. In dialogue with our customers, we optimise our products to meet the specific application requirements. AILIAI develops the best alloy material solutions for current and future challenges.
獲取更多我們供應的合金和服務信息，請致電086-021-67660801或發電子郵件kefu@ailiaigroup.com聯系我們，您也可以通過微博，微信，領英和推特與我們互動。
For more information on the alloys and services that we supply,?call us?at 086-021-67660801 or email us at kefu@ailiaigroup.com. You can also get in touch on social media, we are constantly active on?Weibo,?Weixin,?LinkedIn?and?Twitter.